Risk of cancers during interrupted antiretroviral therapy in the SMART study. - Wikidata - wikimedia - TriplyDB

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

http://www.wikidata.org/entity/Q34667603

about

Lung cancer in HIV-infected patients in the combination antiretroviral treatment era Developing clinical strength-of-evidence approach to define HIV-associated malignancies for cancer registration in Kenya Human papillomavirus-related diseases in HIV-infected individuals Long-term nitrite inhalant exposure and cancer risk in MSM.Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers HIV infection and the risk of cancers with and without a known infectious cause.Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection.HIV and cancer in Germany An internationally generalizable risk index for mortality after one year of antiretroviral therapy.Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials.Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008 Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons.Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary?Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings Increased Natural Killer Cell Activation in HIV-Infected Immunologic Non-Responders Correlates with CD4+ T Cell Recovery after Antiretroviral Therapy and Viral Suppression.Cancer prevention in HIV-infected populations.CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?HIV-associated bladder cancer: a case series evaluating difficulties in diagnosis and management.Evolving spectrum and incidence of non-AIDS-defining malignancies.Cutaneous malignancies among HIV-infected persons.Motivation and patch treatment for HIV+ smokers: a randomized controlled trial.Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk Cancer incidence in a Nationwide HIV/AIDS patient cohort in Taiwan in 1998-2009.Considerations for Endpoint Selection When Designing HIV Clinical Trials.Incidence and risk of lung cancer in HIV-infected patients.A cure for HIV: is it in sight?Towards an HIV-1 cure: measuring the latent reservoir.Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.

P2860

Q26769769-25831715-D4EE-4BCA-886F-C88D51207320 Q28539066-6C10F474-1AE2-43BD-BE47-A4ACCAEC8BD2 Q33395603-4FBBF53D-F196-4AC8-99C0-C78903CA392C Q33631041-88AF07AC-C61E-4B66-8C50-1CA3049DB97A Q33651611-53EBF577-25C7-45B1-9C0B-C488C1B1F2C7 Q33696149-4F7473AA-10DF-4D89-B398-8398B06CFE3A Q33713347-AF7AD516-DEB1-447F-9381-C977A42EC7E4 Q33827510-EE22F7DB-594D-4B79-ADE2-DBA8662B1F53 Q34011661-03C8CB62-20E6-4226-B0EC-1C69EB445FE0 Q34050143-907A4736-3B21-4E4C-9715-FD2E7704A7B5 Q34660212-767D1C29-E95E-4116-B508-E7EE1982CC98 Q34813110-8D7E9DEB-B853-421B-B9E7-B728383845D4 Q35030752-8643B079-5D9B-4353-9B5C-7EA15EDF31B4 Q35063571-83B307B5-E2A9-469B-9D80-A0523F3B8D04 Q35129228-B83FDCBF-2E80-4645-97AC-1A62366CEA60 Q35250302-F58A0A26-03AC-45ED-8F73-54B3C5DE0A7E Q35562938-E8228E3D-7748-42AA-8485-CBD7F0983E66 Q35850380-6EF80E4E-6C29-4CBE-AF80-67D6CA7AFB86 Q35958548-80745CC9-BA81-49BB-B819-48D1352EA8C2 Q36036666-BB122BE7-7392-4376-94EC-26436835792E Q36132370-4FD9B4AD-1DD9-44E2-8695-DE01E04FF688 Q36162341-C4EC45FB-D1CD-478B-912A-45035D093218 Q36246252-120C704B-77E3-4B87-B5C0-595D12CF7F56 Q36680086-C9401B7E-F26D-4BDD-B020-F95E452414D8 Q36745251-4224C622-B838-4B8C-A6AE-3AD7FAB7A14C Q36859148-61212820-5E9C-41A6-98FD-DC75BA9BA9B6 Q36875697-E8273BBD-9231-4FB0-AA9C-4504B70924E2 Q37178883-61835E0D-8086-4984-B91C-E01CAEE6A17B Q37233212-B8CA9540-2E17-44B6-97C6-5B3540A8A857 Q37351970-8E732B65-4785-4044-8183-B03224F14D6F Q37353390-7D62EB49-0EC3-4E92-9673-7955DB97B3DF Q37387284-36BDFE8E-B8D1-4607-A0D3-1E6BC790D8D4 Q37389719-010B593E-D230-4588-9BBC-5A739B24C9E0 Q37712406-4AE8CEB1-D915-44CA-A662-3A141917C63E Q37717137-BF4EB646-49B1-4C10-A541-74748749A6ED Q37967498-6CC30A55-FDFF-403C-9430-D55FEBBFF32E Q38124683-6248A622-F572-4325-B857-9DD2F17530BD Q38205472-739DA1DD-0644-459D-BA93-CBA1B301FBE6 Q38369541-31096D49-343C-4348-AC1A-8000097787F4 Q38853095-267361EB-C679-41A0-B12D-DC2BE2FA027D

P2860

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

http://www.wikidata.org/entity/Q34667603

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@ast

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@en

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@nl

type

label

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@ast

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@en

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@nl

prefLabel

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@ast

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@en

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@nl

P1433

Q34667603-2F09C406-5A8A-43D8-82C6-1CFDF0DCFA5E

P1476

Q34667603-3F69C743-89D5-4653-A01A-5D5690CBC576

P2093

Q34667603-19449629-5B17-40BE-BDFE-D9E2871FE5EB

Q34667603-19A3A6CB-A6CC-4B0B-A456-AC57F133CA8C

Q34667603-1D2EEB3B-30D0-47F9-B1F8-64D16FC93958

Q34667603-A222D267-DD08-4068-9B10-4884BAA5507E

Q34667603-AE98A5B2-2081-49EA-881E-F9838A65C8CF

Q34667603-B4519351-5320-47C5-9E0A-B9EF796ECE6A

Q34667603-BA1AB3C5-F95A-4D42-97EF-440DBDC6B855

Q34667603-DD2BD62F-7CB8-4CDE-8585-93F4F3E027A8

Q34667603-E8D655A8-A964-4E84-8269-1006C77E31A7

P304

Q34667603-B6BA0268-74A7-46CB-B909-F29CBDCADBDD

P31

Q34667603-3374A459-8C0A-4B63-B54C-0173BDC4709A

P356

Q34667603-755B06E4-3C42-40D7-9A84-55A91CCAA2BD

P407

Q34667603-EF578BCA-2334-4F01-9D7C-5207F4E96B5C

P433

Q34667603-177DB948-BD7F-4479-9F4B-8C5D1391E99B

P478

Q34667603-B1796BC4-236A-433B-AB6A-26A7DA36854E

P50

Q34667603-1C8676E2-23D6-45AE-A6C7-1E487BBFF244

Q34667603-DBCAC6C8-0DAE-4A46-8145-D899EBC30396

P577

Q34667603-EB6C389F-1E42-4B3F-833B-1B93BFCBAD5B

P698

Q34667603-2AECD605-1858-45B1-A2B3-DC6F0B86E66A

P921

Q34667603-23851B10-53A1-470D-B082-932A4371645D

P356

QAD.0B013E3282ED6338

P1433

P1476

Risk of cancers during interrupted antiretroviral therapy in the SMART study.

@en

P2093

Angelos Hatzakis

http://www.w3.org/2001/XMLSchema#string

Daniela Gey

http://www.w3.org/2001/XMLSchema#string

Donald I Abrams

http://www.w3.org/2001/XMLSchema#string

Jacqueline Neuhaus

http://www.w3.org/2001/XMLSchema#string

James D Neaton

http://www.w3.org/2001/XMLSchema#string

Jose Hidalgo

http://www.w3.org/2001/XMLSchema#string

Keith Henry

http://www.w3.org/2001/XMLSchema#string

Leonardo Lourtau

http://www.w3.org/2001/XMLSchema#string

Michael J Silverberg

http://www.w3.org/2001/XMLSchema#string

P304

1957-1963

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E3282ED6338

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Tambussi

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17721103

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug